Yayın: Comparison of the neuroprotective effects of gossypin on cisplatin-induced neurotoxicity in vitro and in vivo
| dc.contributor.author | Cinar, Irfan | |
| dc.contributor.author | Yayla, Muhammed | |
| dc.contributor.author | Bayram, Pınar | |
| dc.contributor.author | Binnetoğlu, Damla | |
| dc.date.accessioned | 2026-01-04T20:42:44Z | |
| dc.date.issued | 2024-07-19 | |
| dc.description.abstract | <title>Abstract</title> <p><bold>Aims:</bold>The aim of this study is to investigate the possible protective neuroprotective effects of gossypine (GOS) against cisplatin (CIS) (cis-diamminedichloroplatin [II]) toxicity. <bold>Materials and methods:</bold>CIS (In-vitro; 50 and 100 µM, In-vivo; 10 mg/kg/day) toxicity was created In-vitro and In-vivo, and GOS administration (In-vitro; 50, 75 and 100 µM, In-vivo; 5, 10 and 20 mg/kg/day). <bold>Key findings:</bold>We used different methods that supported each other. In primary neuron culture, cell proliferation was protected against CIS toxicity in a time-dependent manner with applying GOS. Oxidative/antioxidative markers were normalized in a dose-dependent manner with gossypin administration. In the mechanisms of neurotoxic/neuroprotective (iNOS/nNOS) and inhibition of inflammatory mediators (TNF-a and NF-kB), gossypin has been shown to inhibit NF-kB activation to suppress CIS-induced inflammation in primary neuron culture cells. It has been shown to have antiapoptotic effects in healthy tissues and cells by inhibiting CASP-3 and CASP-9 mRNA levels by regulating the ratio of BCL2/BAX, which are pro-apoptotic and anti-apoptotic indicators. <bold>Significance:</bold>We conclude that It has been shown that gossypin may be an ideal neuroprotective agent with potent antioxidant capacity and does not reduce the antitumor activity of the chemotherapeutic drug.</p> | |
| dc.description.uri | https://doi.org/10.1007/s11033-025-10501-7 | |
| dc.description.uri | https://doi.org/10.21203/rs.3.rs-4647701/v1 | |
| dc.description.uri | https://pubmed.ncbi.nlm.nih.gov/40261449 | |
| dc.identifier.doi | 10.1007/s11033-025-10501-7 | |
| dc.identifier.eissn | 1573-4978 | |
| dc.identifier.issn | 0301-4851 | |
| dc.identifier.openaire | doi_dedup___::842f99903e48e429184deaa85b1d536e | |
| dc.identifier.pubmed | 40261449 | |
| dc.identifier.scopus | 2-s2.0-105003260022 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12597/41984 | |
| dc.identifier.volume | 52 | |
| dc.identifier.wos | 001472628800002 | |
| dc.language.iso | eng | |
| dc.publisher | Springer Science and Business Media LLC | |
| dc.relation.ispartof | Molecular Biology Reports | |
| dc.rights | OPEN | |
| dc.subject | Male | |
| dc.subject | Cell Survival | |
| dc.subject | Superoxide Dismutase | |
| dc.subject | NF-kappa B | |
| dc.subject | Brain | |
| dc.subject | Apoptosis | |
| dc.subject | Antineoplastic Agents | |
| dc.subject | Glutathione | |
| dc.subject | Antioxidants | |
| dc.subject | Mice | |
| dc.subject | Oxidative Stress | |
| dc.subject | Neuroprotective Agents | |
| dc.subject | Malondialdehyde | |
| dc.subject | Animals | |
| dc.subject | Neurotoxicity Syndromes | |
| dc.subject | Cisplatin | |
| dc.subject.sdg | 3. Good health | |
| dc.title | Comparison of the neuroprotective effects of gossypin on cisplatin-induced neurotoxicity in vitro and in vivo | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.api.response | {"authors":[{"fullName":"Irfan, Cinar","name":"Irfan","surname":"Cinar","rank":1,"pid":null},{"fullName":"Muhammed, Yayla","name":"Muhammed","surname":"Yayla","rank":2,"pid":null},{"fullName":"Pınar, Bayram","name":"Pınar","surname":"Bayram","rank":3,"pid":null},{"fullName":"Damla, Binnetoğlu","name":"Damla","surname":"Binnetoğlu","rank":4,"pid":null}],"openAccessColor":"hybrid","publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"Male"},"provenance":null},{"subject":{"scheme":"keyword","value":"Cell Survival"},"provenance":null},{"subject":{"scheme":"keyword","value":"Superoxide Dismutase"},"provenance":null},{"subject":{"scheme":"keyword","value":"NF-kappa B"},"provenance":null},{"subject":{"scheme":"keyword","value":"Brain"},"provenance":null},{"subject":{"scheme":"keyword","value":"Apoptosis"},"provenance":null},{"subject":{"scheme":"keyword","value":"Antineoplastic Agents"},"provenance":null},{"subject":{"scheme":"keyword","value":"Glutathione"},"provenance":null},{"subject":{"scheme":"keyword","value":"Antioxidants"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null},{"subject":{"scheme":"keyword","value":"Mice"},"provenance":null},{"subject":{"scheme":"keyword","value":"Oxidative Stress"},"provenance":null},{"subject":{"scheme":"keyword","value":"Neuroprotective Agents"},"provenance":null},{"subject":{"scheme":"keyword","value":"Malondialdehyde"},"provenance":null},{"subject":{"scheme":"keyword","value":"Animals"},"provenance":null},{"subject":{"scheme":"keyword","value":"Neurotoxicity Syndromes"},"provenance":null},{"subject":{"scheme":"keyword","value":"Cisplatin"},"provenance":null}],"mainTitle":"Comparison of the neuroprotective effects of gossypin on cisplatin-induced neurotoxicity in vitro and in vivo","subTitle":null,"descriptions":["<title>Abstract</title> <p><bold>Aims:</bold>The aim of this study is to investigate the possible protective neuroprotective effects of gossypine (GOS) against cisplatin (CIS) (cis-diamminedichloroplatin [II]) toxicity. <bold>Materials and methods:</bold>CIS (In-vitro; 50 and 100 µM, In-vivo; 10 mg/kg/day) toxicity was created In-vitro and In-vivo, and GOS administration (In-vitro; 50, 75 and 100 µM, In-vivo; 5, 10 and 20 mg/kg/day). <bold>Key findings:</bold>We used different methods that supported each other. In primary neuron culture, cell proliferation was protected against CIS toxicity in a time-dependent manner with applying GOS. Oxidative/antioxidative markers were normalized in a dose-dependent manner with gossypin administration. In the mechanisms of neurotoxic/neuroprotective (iNOS/nNOS) and inhibition of inflammatory mediators (TNF-a and NF-kB), gossypin has been shown to inhibit NF-kB activation to suppress CIS-induced inflammation in primary neuron culture cells. It has been shown to have antiapoptotic effects in healthy tissues and cells by inhibiting CASP-3 and CASP-9 mRNA levels by regulating the ratio of BCL2/BAX, which are pro-apoptotic and anti-apoptotic indicators. <bold>Significance:</bold>We conclude that It has been shown that gossypin may be an ideal neuroprotective agent with potent antioxidant capacity and does not reduce the antitumor activity of the chemotherapeutic drug.</p>"],"publicationDate":"2024-07-19","publisher":"Springer Science and Business Media LLC","embargoEndDate":null,"sources":["Crossref"],"formats":null,"contributors":null,"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"Molecular Biology Reports","issnPrinted":"0301-4851","issnOnline":"1573-4978","issnLinking":null,"ep":null,"iss":null,"sp":null,"vol":"52","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::842f99903e48e429184deaa85b1d536e","originalIds":["10501","10.1007/s11033-025-10501-7","50|doiboost____|638fb41ef26ab76cea6a036e1a5ca3a1","10.21203/rs.3.rs-4647701/v1","50|doiboost____|842f99903e48e429184deaa85b1d536e","40261449"],"pids":[{"scheme":"doi","value":"10.1007/s11033-025-10501-7"},{"scheme":"doi","value":"10.21203/rs.3.rs-4647701/v1"},{"scheme":"pmid","value":"40261449"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":0,"influence":2.5349236e-9,"popularity":2.4744335e-9,"impulse":0,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C5"}},"instances":[{"pids":[{"scheme":"doi","value":"10.1007/s11033-025-10501-7"}],"license":"Springer Nature TDM","type":"Article","urls":["https://doi.org/10.1007/s11033-025-10501-7"],"publicationDate":"2025-04-22","refereed":"peerReviewed"},{"pids":[{"scheme":"doi","value":"10.21203/rs.3.rs-4647701/v1"}],"license":"CC BY","type":"Article","urls":["https://doi.org/10.21203/rs.3.rs-4647701/v1"],"publicationDate":"2024-07-19","refereed":"peerReviewed"},{"pids":[{"scheme":"pmid","value":"40261449"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1007/s11033-025-10501-7"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/40261449"],"publicationDate":"2025-04-22","refereed":"nonPeerReviewed"}],"isGreen":false,"isInDiamondJournal":false} | |
| local.import.source | OpenAire | |
| local.indexed.at | WOS | |
| local.indexed.at | Scopus | |
| local.indexed.at | PubMed |
